References
- Tong B, Liu X, Xiao J, Su G. Immunopathogenesis of Behcet’s Disease. Front Immunol. 2019;10:665. doi: 10.3389/fimmu.2019.00665/full
- Nieto IG, Alabau JLC. Immunopathogenesis of Behçet disease. Curr Rheumatol Rev. 2020;16(1):12–20. doi: 10.2174/1573397115666190415142426
- Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, et al. Behcet’s disease in Iran: analysis of 6500 cases. Int J of Rheum Dis. 2010;13(4):367–73. doi: 10.1111/j.1756-185X.2010.01549.x
- Hadjimi Z, Belguendouz H, Benchabane S, Ghozali NEH, Amri M, Kocheida R, et al. Increased Salivary Cytokines and Nitric Oxide Levels in Behçet’s Disease: Interleukin-32, a Novel Player in Disease Prognosis. Endocr Metab Immune Disord Drug Targets. 2023;23(3):347–55. doi: 10.2174/1871530322666220512120948
- Nakamura K, Iwata Y, Asai J, Kawakami T, Tsunemi Y, Takeuchi M, et al. Guidelines for the treatment of skin and mucosal lesions in Behçet’s disease: A secondary publication. J Dermatol. 2020;47(3):223–35. doi: 10.1111/1346-8138.15207
- Deuter C, Kotter I, Wallace G, Murray P, Stubiger N, Zierhut M. Behçet’s disease: Ocular effects and treatment. Prog Retin Eye Res. 2008;27(1):111–36. doi: 10.1016/j.preteyeres.2007.09.002
- Houman MH, Neffati H, Braham A, Harzallah O, Khanfir M, Miled M, et al. Behçet’s disease in Tunisia. Demographic, clinical and genetic aspects in 260 patients. Clin Exp Rheumatol. 2007;25(4 Suppl 45):S58–64.
- Egyptian College of Rheumatology-Behçet’s Disease Study Group (ECR-BDSG), Gheita TA, El-Latif EA, El-Gazzar II, Samy N, Hammam N, et al. Correction to: Behçet’s disease in Egypt: a multicenter nationwide study on 1526 adult patients and review of the literature. Clin Rheumatol. 2019;38(9):2649–50. doi: 10.1007/s10067-019-04653-8
- Ghembaza MEA, Bouabdallah N, Lounici A. Behçet disease in Western Algeria. Médecine et Santé Tropicales. 2017;27(1):101–4. doi: 10.1684/mst.2017.0656
- Kappen JH, van Dijk EHC, Baak-Dijkstra M, van Daele PLA, Lam-Tse WK, van Hagen PM, et al. Behçet’s disease, hospital-based prevalence and manifestations in the Rotterdam area. Neth J Med. 2015;73(10):471–7.
- Melikoğlu MA, Melikoğlu M. The Influence of Age on Behcet’s Disease Activity. Eurasian J Med. 2008;40(2):68–71.
- Kılıç G, Körüklü KF, Kumcu MG, Çakır E, Karkucak M, Kılıç E. Gender disparities in Behçet’s syndrome: identifying distinct phenotypes through cluster analysis. Immunol Res. 2024;72(5):975–81. doi: 10.1007/s12026-024-09498-1
- Chen KR, Kawahara Y, Miyakawa S, Nishikawa T. Cutaneous vasculitis in Behçet’s disease: A clinical and histopathologic study of 20 patients. J Am Acad Dermatol. 1997;36(5):689–96. doi: : 10.1016/S0190-9622(97)80318-0
- Adil A, Goyal A, Quint JM. Behcet Disease. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. Available from:
http://www.ncbi.nlm.nih.gov/books/NBK470257/ - Al-Obeidi AF, Nowatzky J. Immunopathogenesis of Behçet’s disease. Clinical Immunol. 2023;253:109661. 10.1016/j.clim.2023.109661
- Van Der Houwen TB, Van Hagen PM, Van Laar JAM. Immunopathogenesis of Behçet’s disease and treatment modalities. Seminars in Arthritis and Rheumatism. 2022;52:151956. doi: 10.1016/j.semarthrit.2022.151956
- Ortiz-Fernández L, Sawalha AH. Genetics of Behçet’s disease: functional genetic analysis and estimating disease heritability. Front Med. 2021;8:625710. doi: 10.3389/fmed.2021.625710/
- Mattioli I, Bettiol A, Saruhan-Direskeneli G, Direskeneli H, Emmi G. Pathogenesis of Behçet’s syndrome: genetic, environmental and immunological factors. Front Med. 2021;8:713052. doi: 10.3389/fmed.2021.713052
- Sornsamdang G, Shobana J, Chanprapaph K, Chantratita W, Chotewutmontri S, Limtong P, et al. Novel genetic variants of HLA gene associated with Thai Behcet’s disease (BD) patients using next generation sequencing technology. Sci Rep. 2024;14(1):7967. doi: 10.1038/s41598-024-58254-w
- Takeno M. The association of Behçet’s syndrome with HLA-B51 as understood in 2021. Curr Opin Rheumatol. 2022;34(1):4–9. doi: 10.1097/BOR.0000000000000846
- Kim JN, Kwak SG, Choe JY, Kim SK. The prevalence of Behçet’s disease in Korea: data from Health Insurance Review and Assessment Service from 2011 to 2015. Clin Exp Rheumatol. 2017;35 Suppl 108(6):38–42.
- Sakane T, Takeno M, Suzuki N, Inaba G. Behçet’s Disease. N Engl J Med. 1999;341(17):1284–91. doi: 10.1056/NEJM199910213411707
- Hatemi G, Seyahi E, Fresko I, Talarico R, Uçar D, Hamuryudan V. One year in review 2021: Behçet’s syndrome. Clin Exp Rheumatol. 2021;39(5):3–13. doi: 10.55563/clinexprheumatol/lnvc9k
- Leonardo NM, McNeil J. Behcet’s Disease: Is There Geographical Variation? A Review Far from the Silk Road. Int J Rheumatol. 2015;2015:1–7. doi: 10.1155/2015/945262
- Muñoz SA, Kostianovsky A, Allievi A, Orden AO. Behçet disease in Latin American countries: a systematic literature review of demographic and clinical features, and HLA-B*51 allele frequency. Reumatología Clínica (English Edition). 2023;19(7):386–91. doi: 10.1016/j.reumae.2022.12.005
- Gu F, Huang X, Huang W, Zhao M, Zheng H, Wang Y, et al. The role of miRNAs in Behçet’s disease. Front Immunol. 2023;14:1249826. doi: 10.3389/fimmu.2023.1249826/full
- Villiger RA, Stefanski AL, Grobty V, Adler S, Villiger PM. Behçet’s syndrome: clinical presentation and prevalence in Switzerland. Swiss Med Wkly. 2019; 149:w20072. doi: 10.4414/smw.2019.20072
- Leccese P, Padula MC, Santospirito EV, Colucci R, Lascaro N, Padula AA, et al. The relationship between HLA-B*51 subtypes, clinical manifestations and severity of Behçet’s syndrome: a large Italian cohort study. Rheumatology Adv Pract. 2023;7(3):rkad087. doi: 10.1093/rap/rkad087
- Alibaz-Oner F, Direskeneli H. Advances in the treatment of Behçet’s disease. Curr Rheumatol Rep. 2021;23(6):47. doi: 10.1007/s11926-021-01011-z
- Alpsoy E, Leccese P, Emmi G, Ohno S. Treatment of Behçet’s disease: an algorithmic multidisciplinary approach. Front Med. 2021;8:624795. doi: 10.3389/fmed.2021.624795/full
- Kudsi M, Khalayli N, Allahham A. Behcet’s disease: Diagnosed as isolated recurrent oral aphthae; a case report. Ann Med Surg (London). 2022;81. doi: j.amsu.2022.104327
- Moots RJ, Fortune F, Jackson R, Thornburn T, Morgan A, Carr DF, et al. Infliximab vs interferon-α in the treatment of Behçet’s syndrome: clinical data from the BIO-BEHÇET’S randomized controlled trial. Rheumatol. 2025;64(5):2882–91. doi: 10.1093/rheumatology/keae585
- Hatemi G, Mahr A, Ishigatsubo Y, Song YW, Takeno M, Kim D, et al. Trial of Apremilast for oral ulcers in Behçet’s syndrome. N Engl J Med. 2019;381(20):1918–28. doi: 10.1056/NEJMoa1816594
- Geertsema-Hoeve BC, Van Laar JAM, Raaphorst J, Tas SW, Welsing PMJ, Goekoop RJ, et al. Multicentre, 26-weeks, open-label phase 2 trial of the JAK inhibitor filgotinib in Behçet’s disease, idiopathic inflammatory myopathies and IgG4-related disease: DRIMID study protocol. BMJ Open. 2025;15(2):e089827. doi: 10.1136/bmjopen-2024-089827
- Interlandi E, Leccese P, Olivieri I, Latanza L. Adalimumab for treatment of severe Behçet’s uveitis: a retrospective long-term follow-up study. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S58–62.
- Khitri MY, Bartoli A, Maalouf G, Deroux A, Salvarani C, Emmi G, et al. Tocilizumab in Behçet Disease: A Multicenter Study of 30 Patients. J Rheumatol. 2023;50(7):916–23. doi: 10.3899/jrheum.221106
- Davatchi F. Diagnosis/classification criteria for Behcet’s disease. Pathol Res Int. 2012;2012:1–5.doi:
https://doi.org/10.1155/2012/607921 - International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD), Davatchi F, Assaad-Khalil S, Calamia KT, Crook JE, Sadeghi-Abdollahi B, et al. The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. Acad Dermatol Venereol. 2014;28(3):338–47. doi: 10.1111/jdv.12107
- Alibaz-Oner F, Direskeneli H. Update on the Diagnosis of Behçet’s Disease. Diagnostics. 2022;13(1):41. doi: 10.3390/diagnostics13010041
- Wei Y, Li N, Zhao L, Yang C, Ma B, Li X, et al. MicroRNAs and autoimmune-mediated eye diseases. Front Cell Dev Biol. 2020;8:818. doi: 10.3389/fcell.2020.00818/full
- Emmi G, Bagni G, Lastraioli E, Di Patti F, Bettiol A, Fiorillo C, et al. A unique circulating miRNA profile highlights thrombo-inflammation in Behçet’s syndrome. Ann. Rheum. Dis. 2022;81(3):386–97. doi: 10.1136/annrheumdis-2021-220859
- Puccetti A, Pelosi A, Fiore PF, Patuzzo G, Lunardi C, Dolcino M. MicroRNA Expression Profiling in Behçet’s Disease. J. of Immunol Res. 2018;2018:1–18. doi: 10.1155/2018/2405150
- Hussein W, Ramadan H, Labib S, Hegazy G, Shaker O, Yusuf S, et al. Expression levels of lncRNA NEAT1, miRNA-21, and IL-17 in a group of Egyptian patients with Behçet’s disease: relation to disease manifestations and activity. Biol: Targets Ther. 2024;18:327–37. doi: 10.2147/BTT.S493191
- Hassouna SS, Tayel MY, ElKaffash DM, Abdelhady AM, Elsayed EH. MicroRNA155 expression in relation to BDCAF scored Behçet’s disease in an Egyptian patients’ sample. Open Rheumatol J. 2018;12(1):115–22. doi: 10.2174/1874312901812010115
- Lengvári L, Takács K, Lengyel A, Pálinkás A, Wouters CH, Koné-Paut I, et al. Mevalonate kinase deficiency: an updated clinical overview and revision of the SHARE recommendations. Front Immunol. 2024;15:1466844.
- Papa R, Doglio M, Lachmann HJ, Ozen S, Frenkel J, et al. A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry. Orphanet J Rare Dis. 2017;12(1):167. doi: 10.1186/s13023-017-0720-3
- Houten SM, Van Woerden CS, Wijburg FA, Wanders RJA, Waterham HR. Carrier frequency of the V377I (1129G>A) MVK mutation, associated with Hyper-IgD and periodic fever syndrome, in the Netherlands. Eur J Hum Genet. 2003;11(2):196–200. doi: 10.1038/sj.ejhg.5200933
- Feldmann J, Prieur AM, Quartier P, Berquin P, Certain S, Cortis E, et al. Chronic Infantile Neurological Cutaneous and Articular Syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet. 2002;71(1):198–203. doi: 10.1016/S0002-9297(07)60434-0
- Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet. 2001;29(3):301–5. doi: 10.1038/ng756
- Dodé C, Le Dû N, Cuisset L, Letourneur F, Berthelot JM, Vaudour G, et al. New mutations of CIAS1 that are responsible for Muckle-Wells Syndrome and Familial Cold Urticaria: a novel mutation underlies both syndromes. Am J Hum Genet. 2002;70(6):1498–506. doi: 10.1086/340786
- Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): A new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis & Rheumat. 2002;46(12):3340–8. doi: 10.1002/art.10688
- Bertin J, DiStefano PS. The PYRIN domain: a novel motif found in apoptosis and inflammation proteins. Cell Death Differ. 2000;7(12):1273–4. doi: 10.1038/sj.cdd.4400774
- Centola M, Wood G, Frucht DM, Galon J, Aringer M, Farrell C, et al. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood. 2000;95(10):3223–31.
- Lange-Sperandio B, Möhring K, Gutzler F, Mehls O. Variable expression of vasculitis in siblings with familial Mediterranean fever. Pediatr Nephrol. 2004;19(5):539–43. doi: 10.1007/s00467-004-1440-1
- Cattan D, Notarnicola C, Molinari N, Touitou I. Inflammatory bowel disease in non-Ashkenazi Jews with familial Mediterranean fever. The Lancet. 2000;355(9201):378–9. doi: 10.1016/S0140-6736(99)02134-0
- Koné Paut I, Dubuc M, Sportouch J, Minodier P, Garnier JM, Touitou I. Phenotype-genotype correlation in 91 patients with familial Mediterranean fever reveals a high frequency of cutaneomucous features. Rheumatology. 2000;39(11):1275–9. doi: 10.1093/rheumatology/39.11.1275
- Boursier G, Rittore C, Milhavet F, Cuisset L, Touitou I. Mevalonate Kinase-Associated Diseases: Hunting for Phenotype-Genotype Correlation. J Clin Med. 2021;10(8):1552. doi: 10.3390/jcm10081552
- Arslan Taş D, Erken E, Yildiz F, Dinkçi S, Sakalli H. Mevalonate kinase gene mutations and their clinical correlations in Behçet’s disease. Int J of Rheum Dis. 2014;17(4):435–43. doi: 10.1111/1756-185X.12243
- Koné-Paut I, Sanchez E, Le Quellec A, Manna R, Touitou I. Autoinflammatory gene mutations in Behçet’s disease. Ann Rheum Dis. 2007;66(6):832–4. doi: 10.1136/ard.2006.068841
- Yıldız F, Dinkçi S, Erken E. Mevalonate kinase gene polymorphisms in ankylosing spondylitis patients: A cross-sectional study. Arch Rheumatol. 2023;38(2):238–48. doi: 10.46497/ArchRheumatol.2023.9468
- Kuiper JJ, Prinz JC, Stratikos E, Kuśnierczyk P, Arakawa A, Springer S, et al. EULAR study group on ‘MHC-I-opathy’: identifying disease-overarching mechanisms across disciplines and borders. Ann Rheum Dis. 2023;82(7):887–96. doi: 10.1136/ard-2022-222852
- Guasp P, Alvarez-Navarro C, Gomez-Molina P, Martín-Esteban A, Marcilla M, Barnea E, et al. The peptidome of Behçet’s disease–associated HLA–B*51:01 includes two subpeptidomes differentially shaped by endoplasmic reticulum aminopeptidase 1. Arth & Rheum. 2016;68(2):505–15. doi: 10.1002/art.39430
- McGonagle D, Aydin SZ, Gül A, Mahr A, Direskeneli H. ‘MHC-I-opathy’—unified concept for spondyloarthritis and Behçet disease. Nat Rev Rheumatol. 2015;11(12):731–40. doi: 10.1038/nrrheum.2015.147
- Chang HK, Kim JU, Cheon KS, Chung HR, Lee KW, Lee IH. HLA-B51 and its allelic types in association with Behçet’s disease and recurrent aphthous stomatitis in Korea. Clin Exp Rheumatol. 2001;19(5 Suppl 24):S31–35.
- Burillo-Sanz S, Montes-Cano MA, García-Lozano JR, Olivas-Martínez I, Ortego-Centeno N, García-Hernández FJ, et al. Behçet’s disease and genetic interactions between HLA-B*51 and variants in genes of autoinflammatory syndromes. Sci Rep. 2019;9(1):2777. doi: 10.1038/s41598-019-39113-5